We maximize the value of new drugs by identifying new indications with minimum cost and in a shorter time in collaboration with partners.
Drug Signature Transcriptome Data
Disease Transcriptome Data
We identify a new indication other than the original indication of the drug candidate under development.
We identify a combination drug that can improve the efficacy synergistically with the original drug.
Efficient clinical trials can be carried out by identifying the optimal cancer types for the anti-cancer drug under development.
Anti-Cancer Drug Signature Transcriptome Data
Cancer Prognosis Transcriptome Data
Optimal Cancer Type
We identify the optimal cancer types for the given anti-cancer drug.
We identify the companion biomarker for the given anti-cancer drug.
We identify the primary site of the Carcinoma of Unknown Primary (“CUP”) within 42 types of cancers with 99.8% accuracy.
CUP Patient’s Cancer Tissue Transcriptome Data
CUP Primary Site Identification
We identify the primary site of the Carcinoma of Unknown Primary (“CUP”)
Recommend the Optimal Anti-Cancer Treatment
We recommend the optimal treatment according to the original cancer tumor.